Analysts Revise EPS Estimates for Major Companies on January 6

Analysts have updated earnings per share (EPS) estimates for several prominent companies as of January 6. These revisions reflect changes in ratings and target prices from various financial institutions, influencing investor sentiment and market dynamics.

Key Ratings and Target Price Adjustments

Adidas (OTCMKTS: ADDYY) maintained its underperform rating, as reiterated by analysts from Bank of America Corporation. Meanwhile, AptarGroup (NYSE: ATR) received an equal weight rating from Wells Fargo & Company, which has set a target price of $133.00 on the stock.

Analysts at Bank of America Corporation also reaffirmed a neutral rating for Axis Capital (NYSE: AXS), with a revised target price of $115.00, slightly down from the previous estimate of $116.00. Conversely, Anheuser-Busch InBev SA/NV (NYSE: BUD) retained its buy rating from Jefferies Financial Group Inc., indicating continued confidence in the beverage giant’s prospects.

In a notable downgrade, Comcast (NASDAQ: CMCSA) was lowered from a neutral rating to a sell rating by analysts at Arete, which has set a target price of $23.00. Additionally, Canadian Natural Resources (NYSE: CNQ) faced a downgrade from an outperform to an in-line rating by Evercore ISI.

Further updates included Hinge Health (NYSE: HNGE), which saw its buy rating reaffirmed with a target price of $59.00 from Needham & Company LLC.

Additional Notable Changes

Analysts at D. Boral Capital reiterated their buy rating for FibroBiologics (NASDAQ: FBLG), maintaining a price target of $15.00. Meanwhile, Greif (NYSE: GEF) had its equal weight rating from Wells Fargo & Company confirmed, with an increased target price of $72.00, up from $68.00.

In the technology sector, NVIDIA (NASDAQ: NVDA) retained its buy rating from Sanford C. Bernstein. However, Sanofi (NASDAQ: SNY) faced a downgrade from an overweight to an equal weight rating by Barclays PLC.

On the banking front, Wells Fargo & Company (NYSE: WFC) continued to hold its underperform rating, with the target price unchanged at $90.00.

These updates highlight the evolving landscape of corporate performance expectations and investor strategies, as financial analysts continually assess market conditions and company-specific factors. Investors are advised to stay informed about these rating changes as they may significantly influence stock valuations in the near term.